What Are Peptides? A Science-First Primer

I get this question more than any other: "What actually is a peptide?" It sounds simple, but if you want to understand why this compound class has become so central to longevity research — and why the 2026 conversation around peptides has become so loud and so muddled — the answer deserves more than a dictionary definition.

So let's build this from the ground up.

The short answer first

Peptides are short chains of amino acids that act as biological signals. The most-asked questions in 2026 — is Ozempic a peptide? are peptides like steroids? are peptides safe? — all hinge on a distinction most coverage skips: there are three very different categories of peptide that get lumped together.

FDA-approved peptide drugs (semaglutide, tirzepatide, insulin, bremelanotide, HCG, others) are pharmaceutical-grade medications with rigorous clinical trial data and physician-supervised access. Supplement-grade peptides (oral collagen, topical copper peptides, oral NAD+ precursors) operate under entirely different regulations and make no therapeutic claims. Investigational and research-stage peptides — the BPC-157, TB-500, Selank category — are still under study, not approved for human use, and accessed legally only through licensed compounding pharmacies under physician prescription, a status that shifted significantly in February 2026 when HHS announced a partial reversal of the FDA's 2023 restrictions.

Knowing which tier a compound belongs to is the foundation for evaluating anything else about it. This article is the primer that explains the difference.

The basic structure

A peptide is a chain of amino acids connected by peptide bonds. That's it at the structural level. What makes the definition useful is where you draw the lines: a peptide is typically 2 to 50 amino acids long. Below 2, you just have free amino acids. Above 50, you're in protein territory.

That size range matters more than it might seem. Proteins like collagen or insulin are large enough to fold into complex three-dimensional structures, and that folding determines their function. Peptides are smaller — they don't fold into stable tertiary structures the same way — but they're precisely shaped enough to do something remarkably specific: bind to receptors and trigger signals.

Think of it this way. A large protein is a machine with many moving parts. A peptide is a key — small, precise, designed to fit one lock.

Worth noting: the "2 to 50 amino acids" range is biochemistry's loose convention, and different sources put the upper bound anywhere from 20 to 100. There is no universal scientific boundary — the distinction between a long peptide and a small protein is somewhat arbitrary, and serious biochemistry sources acknowledge that. The FDA, however, draws a clean regulatory line: under the rule that defines what counts as a "biological product," anything 40 amino acids or fewer is classified as a peptide and is regulated as a conventional drug. Anything larger is classified as a protein and falls under the biologics framework. That 40-amino-acid bright line is what determines which regulatory pathway a compound takes through the FDA, even when the underlying biochemistry doesn't have a sharp cutoff.

How peptides work as signaling molecules

Your body already uses hundreds of peptides as internal messengers. Insulin is a peptide (51 amino acids, right at the boundary). So is oxytocin (9 amino acids), ghrelin (28 amino acids), and GLP-1 (30 amino acids). These aren't exotic molecules — they're part of the ordinary language your cells use to communicate.

When a peptide binds to its receptor, it triggers a conformational change in that receptor — think of it like pressing a button. That button press activates a downstream signaling cascade inside the cell: changes in gene expression, enzyme activity, protein production, or ion channel behavior.

The specificity is what sets peptides apart from most small-molecule drugs. A small molecule often affects multiple receptor types, which is why drug side effects can be broad. A well-designed peptide can be highly selective — hitting one receptor, in specific tissue types, triggering a defined biological response. That selectivity is why the research community has been so interested in synthetic peptides.

Peptides vs. proteins, amino acids, hormones, and steroids

Five terms get used interchangeably in popular wellness conversation, but they describe genuinely different molecules. Worth disentangling, because the confusion drives a lot of the misinformation.

Amino acids are the smallest units in this family — single molecules the body uses as building blocks. There are 20 standard amino acids in human biology. On their own, they're nutrients; they don't have receptor-binding signaling activity in the way peptides do.

Peptides are short chains of amino acids — 2 to roughly 50, with no universal cutoff. Most have specific receptor targets and signaling functions.

Proteins are longer chains, fold into stable three-dimensional structures, and perform structural, enzymatic, or transport functions. Collagen is a structural protein; hemoglobin is a transport protein; the enzymes that run your metabolism are functional proteins. The largest peptides shade into the smallest proteins; the distinction is partly arbitrary at the boundary.

Hormones are signaling molecules — but the term refers to function, not chemistry. Hormones can be peptides (insulin, oxytocin, ghrelin, GLP-1), they can be steroids (testosterone, estrogen, cortisol), or they can be derived from single amino acids (thyroid hormones, adrenaline). What makes something a hormone is that it's produced in one part of the body and acts on receptors elsewhere — its molecular structure varies widely across the category.

Steroids are an entirely different chemical class. They're built around a four-ring carbon skeleton derived from cholesterol — not from amino acids at all. Anabolic steroids (testosterone, nandrolone, the compounds with athletic-doping reputations) and corticosteroids (cortisol, prednisone) share that ring structure. They bind receptors inside cells and directly modulate gene expression, which is a different mechanism from how most peptides work.

So when someone asks "are peptides like steroids?" — no. They're structurally unrelated, mechanistically different, and regulated under different frameworks. The reason they get linked in popular conversation is that some peptides — particularly growth hormone secretagogues — have appeared in the same athletic-doping discussions as anabolic steroids, which created an association that doesn't reflect the underlying biochemistry. A peptide is a small chain of amino acids; a steroid is a four-ring carbon molecule. They are not the same category of compound.

Why researchers are paying attention

The practical advantages of peptides from a research standpoint come down to a few things.

First, specificity. A peptide designed to mimic GHRH (growth hormone-releasing hormone) binds the GHRH receptor and does what GHRH does — it doesn't randomly activate a dozen other receptor types. That clean mechanism makes it easier to study cause and effect.

Second, endogenous basis. Many of the most studied research peptides are synthetic versions of molecules your body already produces — BPC-157 from gastric juice, GHK-CU from plasma, TB-500 from tissue. The body has evolutionary experience with these molecules, which informs the research on tolerability.

Third, the range of applications. The peptide compounds in our catalog represent different biological systems: growth hormone secretagogues that work through the pituitary axis, tissue repair peptides that activate healing pathways, metabolic peptides that modulate insulin and satiety signaling, and copper peptides that regulate gene expression in connective tissue.

The compound landscape: three tiers of regulatory status

Here is where most articles about peptides go wrong. They lump every peptide into one category — "peptides" — and then make a single safety or efficacy claim across the entire group. That framing is wrong, because peptides span three very different regulatory categories, each with its own safety data, its own legal access pathway, and its own evidence base. Conflating them is what makes online peptide content so confusing.

Tier 1: FDA-approved peptide drugs

These are peptides that have gone through full clinical trials, received FDA approval, and are available by prescription as pharmaceutical drugs. They have rigorous safety profiles, defined indications, and the manufacturing oversight that comes with being a regulated drug. When people talk about "peptide medications" or "peptide drugs," this is the tier they mean.

The most prominent FDA-approved peptide drugs include:

Semaglutide — Wegovy (weight loss), Ozempic (type 2 diabetes and cardiovascular risk reduction), Rybelsus (oral type 2 diabetes). A GLP-1 receptor agonist with the most extensive clinical trial data of any peptide drug in the metabolic space.
Tirzepatide — Mounjaro (type 2 diabetes), Zepbound (obesity, obstructive sleep apnea). A dual GIP/GLP-1 agonist, the first peptide drug to engage two incretin pathways simultaneously.
PT-141 / Bremelanotide — Vyleesi. Approved for hypoactive sexual desire disorder in premenopausal women.
HCG / Human chorionic gonadotropin — Pregnyl, Novarel. Approved for fertility applications, hypogonadism, and certain pediatric conditions. Often misclassified as "research peptide" online; it is in fact an approved drug.
Insulin — the prototype peptide drug, in clinical use for over a century.
Tesamorelin (Egrifta) — approved specifically for HIV-associated lipodystrophy.
Liraglutide (Saxenda, Victoza) — an earlier-generation GLP-1 agonist.

The Lab covers the metabolic peptides in this tier in depth, including the GLP-1 revolution overview explaining how the incretin pathway became the most transformative target in metabolic medicine, and the CagriSema combination that's currently in late-phase trials.

Tier 2: Supplement-grade and cosmetic peptides

These peptides aren't regulated as drugs. They're either dietary supplements (under the DSHEA framework) or cosmetic ingredients (under FDA cosmetic regulation, which is much looser than drug regulation). They make no therapeutic claims, don't require prescription, and have correspondingly different safety expectations than Tier 1.

Oral collagen peptides are the most commonly consumed peptide in the United States — found in collagen powders, supplements, and bone-broth concentrates. Marketed for hair, skin, joint, and gut support. Not one of our featured compounds, but worth naming because it's the peptide most readers have encountered. The evidence is genuinely mixed; some studies show modest skin-elasticity and joint-comfort improvements, others find no clear effect. It's a dietary supplement category, not a Tier 1 drug.
Topical copper peptides (GHK-Cu) are a cosmetic ingredient (INCI name: Copper Tripeptide-1) found in serums and creams. The GHK-Cu deep dive covers the science in detail. Topical formulations are regulated as cosmetics, not drugs.
Oral NAD+ precursors (NMN and NR) are sold as dietary supplements. The NAD+ complete guide covers both the precursor approach and the more direct injectable forms.
Oral glutathione precursors (N-acetylcysteine and related compounds) are supplements aimed at supporting endogenous glutathione production. The glutathione complete guide covers the bioavailability problem and what the research actually supports.

Supplement-grade peptides have very different safety expectations than Tier 1 drugs — primarily because they're not delivered to receptors at therapeutic concentrations and rarely produce dramatic effects. The flip side: they don't have to clear the same clinical-trial bar before reaching the market.

Tier 3: Investigational and research-stage peptides

This is the tier where most of the online peptide conversation actually happens — and where the most regulatory complexity lives. These are peptides with promising preclinical data (animal studies, in vitro work) and limited or absent large human trials. They are not FDA-approved for any therapeutic use. Their legitimate access pathway in the United States is through licensed compounding pharmacies under physician prescription — a channel that narrowed significantly when the FDA placed many of these compounds on its Category 2 restricted list in 2023, and that is reopening as a result of the February 2026 HHS announcement covered in the next section.

The honest framing for this tier is that these are compounds still under study, not approved for this use. Some have plausible mechanisms and consistent preclinical data; some are at the speculative end. Treating them all as either "the next thing" or "scams" both miss the point.

The compounds on The Lab in this tier:

Tissue repair peptides — BPC-157, TB-500, and injectable GHK-Cu. Each remains under study; no FDA approval for any human use.
Growth hormone secretagogues — CJC-1295 without DAC and Ipamorelin, covered in the growth hormone system overview and the Sermorelin vs. HGH comparison.
Nootropic peptides — Selank and Semax. Approved as anxiolytic and neuroprotective drugs in Russia since the 1990s; not approved in the United States.
Longevity-targeted peptides — Epitalon, MOTS-c, and SS-31 / Elamipretide. Different mechanisms, all under active investigation.
Metabolic compounds in trials — Retatrutide (triple-receptor agonist, Phase 3) and 5-Amino-1MQ (NNMT inhibitor, very early-stage human data).
Other — AOD-9604 (HGH fragment that completed Phase 2 with mixed results and was never approved).

For the conceptual framework on why these compounds get studied together, see the peptide stacking primer and the collagen and elastin biology article that grounds the connective-tissue compound research.

A separate warning case: Melanotan II

Melanotan II is technically a peptide, but it does not fit any of the three tiers above and should not be lumped with the Tier 3 compounds that have a legitimate compounding-pharmacy pathway. It is not FDA-approved, was not on the 2023 Category 2 list, and is not on the list of peptides expected to return to Category 1 in 2026. It is sold almost exclusively through grey-market online vendors with no purity testing, no manufacturing oversight, and no medical supervision.

Multiple regulatory bodies have published explicit warnings against it. The US FDA has not approved it for any use. Australia's Therapeutic Goods Administration has issued repeated consumer warnings. Dermatology societies in several countries have flagged it for documented safety concerns including changes to mole pigmentation, kidney events, and priapism. The compound is covered on The Lab specifically because people are using it and deserve honest information about what it is and what the risks look like — not because it belongs in the same conversation as the compounding-pharmacy-accessible peptides.

The 2026 regulatory pivot

One reason peptides are everywhere in 2026 conversation is that the regulatory landscape just shifted in a meaningful way. Here is what actually happened, because most coverage gets it muddled.

In 2023, the FDA placed roughly nineteen widely used peptides — BPC-157, TB-500, CJC-1295, Ipamorelin, Selank, Thymosin Alpha-1, and others — onto the Category 2 list of the interim 503A Bulks List. Category 2 means the FDA had identified safety concerns or insufficient data and was restricting compounding-pharmacy production. The practical effect: licensed pharmacies that had been preparing these compounds for patients with physician prescriptions could no longer legally do so. The cited reasoning involved immunogenicity, peptide-related impurities, and limited human safety data.

On February 27, 2026, during an episode of The Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. announced that approximately fourteen of the originally restricted peptides — including BPC-157 — are expected to move back to Category 1, the status that permits licensed compounding pharmacies to prepare them under physician prescription. Subsequent reporting from BioPharma Dive and Frier Levitt indicated the substances came off Category 2 in April 2026, with the FDA's Pharmacy Compounding Advisory Committee scheduled to formally review compounding status at its July 23–24, 2026 meeting.

Three things matter here and get conflated in the coverage.

First, this is announced direction, not finalized rule. The FDA has not published the formal updated list as of this writing. Reporting varies between twelve and fourteen peptides depending on the counting convention. Treat it as an evolving regulatory pivot, not a settled state.

Second, Category 1 is not FDA approval. None of these peptides have been approved as drugs. Category 1 status permits access through licensed compounding pharmacies under valid physician prescription — a narrow, supervised channel, not over-the-counter availability and not a stamp of efficacy. Anyone saying "BPC-157 is now FDA-approved" has the regulatory picture wrong.

Third, the grey market is unaffected. Websites selling vials labeled "research use only, not for human consumption" were illegal before 2023, remained illegal during the restriction, and remain illegal now. Reclassification doesn't change the law around unregulated peptide sales — it changes only the legitimate medical channel.

What the evidence supports vs. doesn't

Research stages vary significantly across the peptide universe, and the difference matters for evaluating any specific claim.

Tier 1 (FDA-approved peptide drugs) has the strongest evidence base by definition. To earn FDA approval, a peptide drug has gone through Phase 1 (safety in healthy volunteers), Phase 2 (efficacy and dose-finding in patients), and Phase 3 (large randomized controlled trials, typically thousands of participants, against placebo or active comparator). Post-approval, there is ongoing safety monitoring and adverse-event reporting. The semaglutide and tirzepatide datasets in particular include tens of thousands of trial participants and millions of real-world patients. When the evidence supports an effect at this scale, it is genuinely supported.

Tier 2 (supplement-grade and cosmetic peptides) varies enormously. Oral collagen has been studied in modest-sized clinical trials with mixed but generally positive findings for skin elasticity and joint comfort. Topical GHK-Cu has decades of cosmetic research behind it. Oral NAD+ precursors have several published human trials showing they raise blood NAD+ levels, with much less certainty about whether that translates to clinical benefit. The supplement evidence base is real but generally smaller in scale and quality than drug-approval trials.

Tier 3 (investigational/research-stage) is where overstatement is easiest and hardest to support. The pattern is consistent: extensive preclinical data (animal models, in vitro studies), often with consistent and impressive results, but limited or absent human clinical-trial data. BPC-157 is the canonical example — over a hundred animal studies but essentially no large human RCTs. A peptide with forty rat studies showing an effect is not the same evidence as a peptide with three thousand-person randomized trials showing an effect. Both are interesting; they are not the same category of evidence.

The honest reading: most Tier 3 peptides have mechanism plausibility and preclinical signal. They lack the human translation evidence that would justify confident therapeutic claims. That is not a reason to dismiss them — it is the reason they are still under study. It is also the reason that anyone considering them should be having that conversation with a licensed medical provider rather than self-experimenting based on internet promises.

Frequently asked questions

Is Ozempic a peptide?

Yes. Ozempic is the brand name for semaglutide, which is a peptide — a 31-amino-acid chain, slightly modified to extend its half-life. All the GLP-1 weight-loss medications — Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus — are peptide drugs. So is insulin, the prototype peptide medication that has been in clinical use for over a century. Calling Ozempic a peptide is accurate; calling it "a peptide" without context can be misleading, because it groups Ozempic — an FDA-approved, rigorously trialed drug — with research-stage peptides that have a completely different evidence base and regulatory status.

Are peptides the same as steroids?

No. Peptides are short chains of amino acids; steroids are four-ring carbon molecules built from cholesterol. They are structurally unrelated, mechanistically different, and regulated under different frameworks. The reason the two get linked in popular conversation is that some growth-hormone-related peptides have appeared in athletic-doping discussions alongside anabolic steroids — but that is a regulatory overlap, not a chemical or pharmacological one. A peptide and a steroid are no more the same thing than insulin and cholesterol are.

What's the difference between a peptide and a protein?

Both are made of amino acids linked by peptide bonds. The conventional biochemistry distinction is that peptides are short (around 2 to 50 amino acids) and proteins are long (50 or more, sometimes thousands). The boundary is not universal — different sources put it at 20, 30, 50, or 100 amino acids. For FDA regulatory purposes, the line is sharper: anything 40 amino acids or fewer is a peptide and is regulated as a drug, while anything larger is classified as a protein and regulated as a biological product. Functionally, proteins tend to fold into stable three-dimensional structures and perform structural, enzymatic, or transport roles; peptides are smaller, more flexible, and most often act as signaling molecules.

Are peptides safe?

The honest answer is "depends entirely on which peptide and which source." FDA-approved peptide drugs like semaglutide and insulin have well-characterized safety profiles built from thousands of trial participants and millions of real-world patients. Supplement-grade peptides like oral collagen have generally favorable safety records at typical doses. Research-stage peptides accessed through licensed compounding pharmacies under physician supervision carry more uncertainty because long-term human safety data is limited, but the supervision matters significantly. Grey-market peptides sold online with no purity testing, no labeling oversight, and no medical guidance are an entirely different risk category, and that is where most of the actual safety incidents have occurred. "Are peptides safe" is the wrong question. "Is this specific peptide, sourced this way, used in this context, with this medical oversight, safe for someone like me" is the right one.

What does the FDA actually approve?

The FDA approves specific peptide drugs for specific indications. Semaglutide is approved for type 2 diabetes and weight management. Tirzepatide is approved for type 2 diabetes, obesity, and obstructive sleep apnea. Bremelanotide is approved for hypoactive sexual desire disorder in premenopausal women. HCG is approved for fertility and hypogonadism. Insulin is approved for diabetes. Tesamorelin is approved for HIV-associated lipodystrophy. Each approval is for a defined indication, in a defined population, at defined doses. The FDA has not approved BPC-157, TB-500, CJC-1295, Ipamorelin, Selank, Semax, Epitalon, MOTS-c, SS-31, 5-Amino-1MQ, AOD-9604, or Melanotan II for any human use.

What changed with peptides in 2026?

In February 2026, HHS announced that approximately fourteen previously restricted peptides — including BPC-157 — are expected to return to the FDA's Category 1 list, restoring licensed compounding pharmacies' ability to prepare them for patients under physician prescription. As of this writing, the FDA has not finalized the list, and the Pharmacy Compounding Advisory Committee is scheduled to formally review the status in July 2026. Category 1 is not FDA drug approval — it permits compounding access under medical supervision, not over-the-counter sale or therapeutic claims. The grey market for these compounds remains illegal regardless of regulatory classification.